ReviewPharmaceutics2019
Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Gold Nanoparticle-Based Precision Medicine Strategies for Glioblastoma: Current Biomedical Applications and Future Outlook.Molecules (Basel, Switzerland) · 2026Review
- Methylene Blue-Loaded Liposomal Nanocarriers Enhance the Efficacy of Photodynamic Therapy againstACS infectious diseases · 2026Article
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Nanoparticles in the treatment of osteoporosis: recent advances in nanoparticles for the treatment of osteoporosis.RSC advances · 2025Review
- Lipid nanoparticles: Composition, formulation, and application.Molecular therapy. Methods & clinical development · 2025Review
- Small interfering RNA: From designing to therapeutic in cancer.Journal, genetic engineering & biotechnology · 2025Review
- Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.Journal of nanobiotechnology · 2024Review
- Chemistry and Art of Developing Lipid Nanoparticles for Biologics Delivery: Focus on Development and Scale-Up.Pharmaceutics · 2024Review
- Silk Fibroin-Modified Liposome/Gene Editing System Knocks out thePharmaceutics · 2023Article
- Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes.Cancer letters · 2023Article
- Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines.Molecular biotechnology · 2023Review
- New Technological Approaches for Dental Caries Treatment: From Liquid Crystalline Systems to Nanocarriers.Pharmaceutics · 2023Review
- miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4.Cell death discovery · 2023Article
- Tailoring the Lamellarity of Liposomes Prepared by Dual Centrifugation.Pharmaceutics · 2023Article
- Self-Assembly of Tunable Intrinsically Disordered Peptide Amphiphiles.Biomacromolecules · 2023Article
- RNA therapeutics in the clinic.Bioengineering & translational medicine · 2023Review
- Article
- Ultrasound Triggering of Liposomal Nanodrugs for Cancer Therapy: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Lipid-Based Drug Delivery Systems for Diseases Managements.Biomedicines · 2022Review
- Smart gene therapeutics for selective targeting of myofibroblasts derived from hepatic stellate cells and limited expression under inflamed conditions.Clinical and translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in gene therapy has had a great impact in the medical field, holding enormous promise, becoming "the latest generation medicine" with the first ever siRNA-lipid based formulation approved by the United States Food and Drug Administration (FDA) for human use, and currently on the market under the trade name Onpattro™. The growth of such powerful biologic therapeutics has gone hand in hand with the progress in delivery systems technology, which is absolutely required to improve their safety and effectiveness. Lipid carrier systems, particularly liposomes, have been proven to be the most suitable vehicles meeting NABDs requirements in the medical healthcare framework, limiting their toxicity, and ensuring their delivery and expression into the target tissues. In this review, after a description of the several kinds of liposomes structures and formulations used for in vitro or in vivo NABDs delivery, the broad range of siRNA-liposomes production techniques are discussed in the light of the latest technological progresses. Then, the current status of siRNA-lipid delivery systems in clinical trials is addressed, offering an updated overview on the clinical goals and the next challenges of this new class of therapeutics which will soon replace traditional drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.